Page last updated: 2024-10-14
apoptolidin
Description
apoptolidin: an apoptosis inducer in transformed cells from Nocardiopsis sp.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11297771 |
| CHEMBL ID | 4096158 |
| MeSH ID | M0294443 |
Synonyms (14)
| Synonym |
|---|
| apoptolidin |
| apoptolidin a |
| 194874-06-1 |
| apoptolidin [mi] |
| sao6wvq23i , |
| unii-sao6wvq23i |
| fu-40a |
| CS-0106791 |
| HY-126679 |
| (3e,5e,7e,9r,10r,11e,13e,17s,18s,20s)-20-[(r)-{(2r,3r,4s,5r,6r)-2,4-dihydroxy-6-[(2r)-2-{[(2r,4s,5s,6s)-4-hydroxy-5-{[(2s,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4,6-dimethyloxan-2-yl]oxy}-3-methoxypropyl]-3,5-dimethyloxan-2-yl}(hydroxy)methy |
| CHEMBL4096158 |
| Q27289111 |
| zh7 , |
| (3~{e},5~{e},7~{e},9~{r},10~{r},11~{e},13~{e},17~{s},18~{s},20~{s})-18-methoxy-20-[(~{r})-[(2~{r},3~{r},4~{s},5~{r},6~{r})-6-[(2~{r})-3-methoxy-2-[(2~{r},4~{s},5~{s},6~{s})-5-[(2~{s},4~{r},5~{r},6~{r})-4-methoxy-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4,6-dimet |
Research Excerpts
Overview
Apoptolidin is a macrolide originally identified on the basis of its ability to selectively kill E1A/E1B19K transformed rat glial cells. It is a natural product that selectively induces apoptosis in several cancer cell lines.
| Excerpt | Reference |
|---|---|
| "Apoptolidin is a natural product that selectively induces apoptosis in several cancer cell lines. " | ( Apoptolidin: induction of apoptosis by a natural product. Daniel, PT; Koert, U; Schuppan, J, 2006) |
| "Apoptolidin is a macrolide originally identified on the basis of its ability to selectively kill E1A and E1A/E1B19K transformed rat glial cells while not killing untransformed glial cells. " | ( Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Herzenberg, LA; Khosla, C; Salomon, AR; Voehringer, DW, 2001) |
Effects
| Excerpt | Reference |
|---|---|
| "Apoptolidin A has been described among the top 0.1% most-cell-selective cytotoxic agents to be evaluated in the NCI 60 cell line panel. " | ( Fluorescent probes of the apoptolidins and their utility in cellular localization studies. Bachmann, BO; Chong, KM; Crews, BA; Daniel, C; DeGuire, SM; Du, Y; Earl, DC; Jacobs, AT; Marnett, LJ; Piston, DW; Sulikowski, GA; Ustione, A, 2015) |
Actions
| Excerpt | Reference |
|---|---|
| "Isoapoptolidin's ability to inhibit mitochondrial F0F1-ATPase is over 10-fold less than that of apoptolidin." | ( Isoapoptolidin: structure and activity of the ring-expanded isomer of apoptolidin. Gulledge, AV; Jankowski, OD; Seto, H; Wender, PA, 2002) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1743698 | Inhibition of F0F1-ATP synthase in yeast intact mitochondria by LDH/pyruvate kinase coupled enzyme assay | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Why All the Fuss about Oxidative Phosphorylation (OXPHOS)? |
| AID1743699 | Inhibition of yeast mitochondrial F0F1-ATP synthase by LDH/pyruvate kinase coupled enzyme assay | 2020 | Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23 | Why All the Fuss about Oxidative Phosphorylation (OXPHOS)? |
| AID1475813 | Inhibition of bovine heart mitochondrial ATP synthase activity assessed as decrease in ATP-dependent NADH oxidation at 1 uM measured every 30 secs for 30 mins by colorimetric assay relative to control | 2017 | Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18 | New Mandelalides Expand a Macrolide Series of Mitochondrial Inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (43)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.33) | 18.2507 |
| 2000's | 30 (69.77) | 29.6817 |
| 2010's | 9 (20.93) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (6.98%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 40 (93.02%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||